{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:41:28Z","timestamp":1789908088291,"version":"4.0.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Continuous administration of low doses of cyclophosphamide and standard doses of cyclooxygenase-inhibiting drugs has been shown to suppress tumor angiogenesis, reverse immunosuppression, and deplete regulatory T cells in cancer models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>We hypothesized that continuous treatment with low-dose cyclophosphamide and full-dose piroxicam would delay tumor recurrence in dogs with soft tissue sarcomas (STS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Eighty-five dogs with incompletely resected STS, 30 treated dogs, and 55 contemporary control dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Treatment outcomes in 85 dogs with incompletely resected STS were evaluated in a retrospective study. Dogs in the treatment group received continuously administered low-dose cyclophosphamide (10\u2003mg\/m2) and standard dose piroxicam (0.3\u2003mg\/kg) therapy. Time to local tumor recurrence (disease-free interval; DFI) was compared between the 30 treated dogs and 55 untreated control dogs matched for age and tumor site and grade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DFI was significantly (P &amp;lt; .0001) prolonged for STS of all sites (trunk and extremity) in treated dogs compared with untreated control dogs. The DFI also was significantly longer in treated dogs when tumor site (trunk and extremity) was compared. Twelve treated dogs (40%) experienced mild toxicity (grade 1 and 2) at some point during treatment and 1 dog developed grade 4 cystitis. Every other day dosing was tolerated better than daily dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metronomic therapy with cyclophosphamide and piroxicam was very effective in preventing tumor recurrence in dogs with incompletely resected STS. These findings suggest that further evaluation of this approach is warranted as adjuvant therapy in dogs with highly metastatic tumors such as osteosarcoma and melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2008.0179.x","type":"journal-article","created":{"date-parts":[[2009,1,22]],"date-time":"2009-01-22T12:15:28Z","timestamp":1232626528000},"page":"1373-1379","source":"Crossref","is-referenced-by-count":136,"title":["Metronomic Therapy with Cyclophosphamide and Piroxicam Effectively Delays Tumor Recurrence in Dogs with Incompletely Resected Soft Tissue Sarcomas"],"prefix":"10.1093","volume":"22","author":[{"given":"R.E.","family":"Elmslie","sequence":"first","affiliation":[{"name":"Veterinary Cancer Specialists , Englewood, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Glawe","sequence":"additional","affiliation":[{"name":"Veterinary Cancer Specialists , Englewood, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.W.","family":"Dow","sequence":"additional","affiliation":[{"name":"Animal Cancer Center, Colorado State University Department of Clinical Sciences, , Ft. Collins, CO"},{"name":"Immunology, and Pathology, Colorado State University Department of Microbiology, , Ft. Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,11,1]]},"reference":[{"key":"2026020304253264400_b1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"key":"2026020304253264400_b2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","article-title":"Angiogenesis","volume":"57","author":"Folkman","year":"2006","journal-title":"Annu Rev Med"},{"key":"2026020304253264400_b3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2026020304253264400_b4","first-page":"427","article-title":"Antiangiogenic scheduling of lower dose cancer chemotherapy","volume":"7","author":"Gately","year":"2001","journal-title":"Cancer J"},{"key":"2026020304253264400_b5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2026020304253264400_b6","first-page":"1195","article-title":"Redefining the target","volume":"19","author":"Miller","year":"2001","journal-title":"Chemotherapeutics as antiangiogenics"},{"key":"2026020304253264400_b7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1248\/bpb.27.599","article-title":"Cancer anti-angiogenic therapy","volume":"27","author":"Shimizu","year":"2004","journal-title":"Biol Pharm Bull"},{"key":"2026020304253264400_b8","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2005-04-1422","article-title":"Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity","volume":"106","author":"Shaked","year":"2005","journal-title":"Blood"},{"key":"2026020304253264400_b9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00001813-200602000-00001","article-title":"From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials","volume":"17","author":"Lam","year":"2006","journal-title":"Anticancer Drugs"},{"key":"2026020304253264400_b10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2005-11-4570","article-title":"Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy","volume":"108","author":"Mancuso","year":"2006","journal-title":"Blood"},{"key":"2026020304253264400_b11","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1073\/pnas.2135406100","article-title":"Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy","volume":"100","author":"Bocci","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020304253264400_b12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0463.2004.apm11207-0809.x","article-title":"Endogenous angiogenesis inhibitors","volume":"112","author":"Folkman","year":"2004","journal-title":"APMIS"},{"key":"2026020304253264400_b13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/0008-5472.CAN-06-3282","article-title":"Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer","volume":"67","author":"Kamat","year":"2007","journal-title":"Cancer Res"},{"key":"2026020304253264400_b14","first-page":"40","article-title":"Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination","volume":"30","author":"Salem","year":"2007","journal-title":"Creation of a beneficial host microenvironment involving type I IFNs and myeloid cells (1997)"},{"key":"2026020304253264400_b15","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0959-8049(00)00044-7","article-title":"Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide","volume":"36","author":"Matar","year":"2000","journal-title":"Eur J Cancer"},{"key":"2026020304253264400_b16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"2026020304253264400_b17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000071373","article-title":"Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis","volume":"37","author":"Gately","year":"2003","journal-title":"Prog Exp Tumor Res"},{"key":"2026020304253264400_b18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1026575610124","article-title":"The contributions of cyclooxygenase-2 to tumor angiogenesis","volume":"19","author":"Gately","year":"2000","journal-title":"Cancer Metastasis Rev"},{"key":"2026020304253264400_b19","first-page":"625","article-title":"Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo","volume":"62","author":"Leahy","year":"2002","journal-title":"Cancer Res"},{"key":"2026020304253264400_b20","first-page":"1306","article-title":"Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors","volume":"60","author":"Masferrer","year":"2000","journal-title":"Cancer Res"},{"key":"2026020304253264400_b21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00262-007-0417-x","article-title":"Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner","volume":"57","author":"Yaqub","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"2026020304253264400_b22","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/0008-5472.CAN-05-0141","article-title":"Tumor cyclooxygenase-2\/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer","volume":"65","author":"Sharma","year":"2005","journal-title":"Cancer Res"},{"key":"2026020304253264400_b23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4049\/jimmunol.175.3.1483","article-title":"Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells","volume":"175","author":"Baratelli","year":"2005","journal-title":"J Immunol"},{"key":"2026020304253264400_b24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4049\/jimmunol.177.1.246","article-title":"FOXP3+ CD4+ CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism","volume":"177","author":"Mahic","year":"2006","journal-title":"J Immunol"},{"key":"2026020304253264400_b25","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1158\/1078-0432.CCR-06-0474","article-title":"High-dose celecoxib and metronomic \u201clow-dose\u201d cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma","volume":"12","author":"Buckstein","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2026020304253264400_b26","first-page":"377","article-title":"Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma","volume":"52","author":"Spieth","year":"2003","journal-title":"A pilot study"},{"key":"2026020304253264400_b27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1215\/15228517-2007-006","article-title":"Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults","volume":"9","author":"Kesari","year":"2007","journal-title":"Neuro Oncol"},{"key":"2026020304253264400_b28","first-page":"356","article-title":"Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer","volume":"62","author":"Mohammed","year":"2002","journal-title":"Cancer Res"},{"key":"2026020304253264400_b29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-4615-0193-0_58","article-title":"Antitumor effects of piroxicam in spontaneous canine invasive urinary bladder cancer, a relevant model of human invasive bladder cancer","volume":"507","author":"Knapp","year":"2002","journal-title":"Adv Exp Med Biol"},{"key":"2026020304253264400_b30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1939-1676.1994.tb03232.x","article-title":"Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder","volume":"8","author":"Knapp","year":"1994","journal-title":"J Vet Intern Med"},{"key":"2026020304253264400_b31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2460\/ajvr.1995.56.06.801","article-title":"Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells","volume":"56","author":"Knapp","year":"1995","journal-title":"Am J Vet Res"},{"key":"2026020304253264400_b32","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2460\/javma.231.7.1056","article-title":"Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder","volume":"231","author":"Greene","year":"2007","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304253264400_b33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1939-1676.2007.tb03019.x","article-title":"Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs","volume":"21","author":"Lana","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020304253264400_b34","first-page":"173","article-title":"Soft-tissue sarcomas","volume":"10","author":"Thrall","year":"1995","journal-title":"Semin Vet Med Surg (Small Anim)"},{"key":"2026020304253264400_b35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0195-5616(97)50012-X","article-title":"Soft tissue sarcomas","volume":"27","author":"Mauldin","year":"1997","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"6","key":"2026020304253264400_b36","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1080\/01652176.1998.10807387","article-title":"Soft tissue sarcomas","volume":"20","author":"Withrow","year":"1998","journal-title":"Vet Q"},{"key":"2026020304253264400_b37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1939-1676.2000.tb02279.x","article-title":"Postoperative radiotherapy for canine soft tissue sarcoma","volume":"14","author":"Forrest","year":"2000","journal-title":"J Vet Intern Med"},{"key":"2026020304253264400_b38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3109\/07357900009012210","article-title":"Spontaneously occurring tumors of companion animals as models for human cancer","volume":"18","author":"Vail","year":"2000","journal-title":"Cancer Invest"},{"key":"2026020304253264400_b39","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.mph.0000243657.64056.c3","article-title":"A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors","volume":"28","author":"Stempak","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026020304253264400_b40","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.exphem.2006.04.013","article-title":"Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation","volume":"34","author":"Lamerato-Kozicki","year":"2006","journal-title":"Exp Hematol"},{"key":"2026020304253264400_b41","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/sj.bjc.6602474","article-title":"Can a rational design for metronomic chemotherapy dosing be devised?","volume":"92","author":"Maraveyas","year":"2005","journal-title":"Br J Cancer"},{"key":"2026020304253264400_b42","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1158\/1535-7163.MCT-07-0181","article-title":"Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice","volume":"6","author":"Emmenegger","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2026020304253264400_b43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.vetimm.2006.12.002","article-title":"Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer","volume":"116","author":"Biller","year":"2007","journal-title":"Vet Immunol Immunopathol"},{"key":"2026020304253264400_b44","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"2026020304253264400_b45","first-page":"1388","article-title":"Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide","volume":"222","author":"Charney","year":"2003","journal-title":"216 cases (1990\u20131996)"},{"key":"2026020304253264400_b46","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-05-0765","article-title":"Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy","volume":"65","author":"Shaked","year":"2005","journal-title":"Cancer Res"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2008.0179.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/6\/1373\/66673832\/j.1939-1676.2008.0179.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/6\/1373\/66673832\/j.1939-1676.2008.0179.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:25:45Z","timestamp":1770110745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/22\/6\/1373\/8449946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,1]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2008.0179.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,11]]},"published":{"date-parts":[[2008,11,1]]}}}